Is JNJ a good stock?
Valuation metrics show that Johnson & Johnson may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
Should you buy JNJ stock?
- EPS: US$1.93 (down from US$2.36 in 1Q 2021).
- Revenue: US$23.4b (up 5.0% from 1Q 2021).
- Net income: US$5.15b (down 17% from 1Q 2021).
- Profit margin: 22% (down from 28% in 1Q 2021). Higher expenses drove the decrease in the margin.
Is JNJ stock a buy or sell?
With a beta of 0.71, JNJ is the definition of a defensive stock. While strong share price growth should not be expected from this behemoth, when one also considers its status as a dividend aristocrat, as well as its sterling financial profile, JNJ stands out as a stock for risk averse investors. I rate JNJ as a BUY.
How to buy JNJ stock?
Johnson & Johnson and the three largest U.S. drug distributors have agreed to move forward with a proposed $26 billion settlement to more than 3,000 civil lawsuits from states and local governments over the companies’ role in the opioid epidemic that has ...
See more
Is JNJ a Buy Sell or Hold?
For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is JNJ a good stock to buy now?
JNJ delivered favorable financial results at the year-end of 2021, with its growth substantially larger than that of competitors. With its steadily growing EPS, the company's dividend yield of 2.57% stands significantly above the S&P 500 average of 1.57%, adding to the reasons why JNJ is a clear market favorite.
When was the last time JNJ stock split?
The last stock split announced by Johnson & Johnson was in 1996, when shares were split 2-for-1. On April 17, Johnson & Johnson announced sales and earnings for the first quarter of 2001. Sales of $7.8 billion and net earnings of $1.5 billion increased by 6.5% and 14.2%, respectively, over first-quarter 2000 results.
What is JNJ target price?
Stock Price Target JNJHigh$215.00Median$187.00Low$174.00Average$188.29Current Price$171.69
Does JNJ increase dividend in 2022?
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.
Is JNJ overvalued?
The intrinsic value of one JNJ stock under the Base Case scenario is 138.42 USD. Compared to the current market price of 178.23 USD, Johnson & Johnson is Overvalued by 22%.
What will happen to JNJ stock when it splits?
19. Rachel Warren: If you currently own shares of Johnson & Johnson like I do, when the company splits, you will own shares of both Johnson & Johnson, the new pharmaceutical/medical device entity, as well as the new yet-to-be-named consumer health business.
Will JNJ stock split soon?
The split isn't expected to happen until the end of 2023. Duato also told investors that the pandemic sped up trends like same-day delivery within the consumer health business.
What does the JNJ split mean?
Johnson & Johnson, the biggest pharmaceutical company in the U.S. based on market cap, announced in November 2021 it plans to spin off its consumer business into a new publicly traded company by November 2023. Analysts overwhelmingly say it's a smart business move, but it could also come with some risks.
What is the target price for Pfizer?
Stock Price TargetsHigh$75.00Median$55.00Low$43.00Average$55.95Current Price$51.37
What is the target price for Disney?
Stock Price TargetHigh$176.00Low$110.00Average$136.15Current Price$99.61
What is the target price for Microsoft?
Stock Price TargetsHigh$400.00Median$347.00Low$298.18Average$345.84Current Price$254.08
Is Johnson & Johnson stock a Buy, Sell or Hold?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 18 buy ratings, 6 hold ratings, and...
What was the 52-week low for Johnson & Johnson stock?
The low in the last 52 weeks of Johnson & Johnson stock was 155.72. According to the current price, Johnson & Johnson is 110.81% away from the 52-w...
What was the 52-week high for Johnson & Johnson stock?
The high in the last 52 weeks of Johnson & Johnson stock was 186.69. According to the current price, Johnson & Johnson is 92.43% away from the 52-w...
What are analysts forecasts for Johnson & Johnson stock?
The 24 analysts offering price forecasts for Johnson & Johnson have a median target of 185.04, with a high estimate of 210.00 and a low estimate of...
What are Johnson and Johnson products?
Where is Johnson and Johnson located?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
What are Johnson and Johnson products?
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. Read More.
Where is Johnson and Johnson located?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women’s health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
What is Johnson and Johnson's biggest strength?
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Is ZacksTrade a separate company?
Johnson & Johnson’s biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. It comprises some 250 subsidiaries, which clearly means that the business is extremely well diversified. Its diversification helps it to withstand economic cycles more effectively. Meanwhile, J&J has one of the largest research and development (R&D) budget among pharma companies.#N#New Brunswick, NJ based J&J’s worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. In 2020, these segments contributed 55%, 38% and 17%, respectively, to the ...
Ownership
- Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol \"JNJ.\" Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), Northern Trust Corp (1.30%), Boston Partners (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Swiss National Bank (0.37%) an…
Release
- Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July 16th 2019. View Earnings Estimates for Johnson & Johnson.
Sales
- Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided earnings per share (EPS) guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 …
Risks
- 11 brokerages have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $146.00 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
Ratings
- 11 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Johnson & Johnson.
Reviews
- News headlines about JNJ stock have been trending positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson ea…
Business
- Johnson & Johnson has a market capitalization of $368.09 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.